TMM News

Global leaders in regenerative medicine gather in Vancouver for the 2026 Till & McCulloch Meetings

Global leaders in regenerative medicine gather in Vancouver for the 2026 Till & McCulloch Meetings

Global leaders in regenerative medicine gather in Vancouver for the 2026 Till & McCulloch Meetings

Nearly 450 researchers, clinicians, trainees, and industry leaders convene to share scientific advances, strengthen collaborations, and explore the future of regenerative medicine.

VANCOUVER, November 9, 2026 – The Stem Cell Network (SCN) is welcoming nearly 450 researchers, clinicians, trainees, and industry leaders to Vancouver for the 2026 Till & McCulloch Meetings (TMM), Canada’s premier stem cell, gene therapies, and regenerative medicine conference.

Taking place November 9-11, TMM2026 will showcase advances in regenerative medicine, foster scientific exchange, and build connections across Canada’s research and innovation ecosystem. This year’s conference also marks a special milestone as SCN celebrates 25 years of supporting regenerative medicine research, talent, and innovation in Canada.

“Over the last 25 years, we’ve seen remarkable progress in regenerative medicine research, and TMM has become an important forum for sharing discoveries and forging new collaborations,” said Dr. Michael Rudnicki, Scientific Director of the Stem Cell Network. “We are now in the midst of a revolution where regenerative medicine is transforming clinical practice. As we look to the future, convening leading scientists, emerging talent, and partners from across the field is essential to continue to translate scientific breakthroughs into new therapies that will improve patients’ lives.”

“Canada is home to some of the world’s leading talent and research in regenerative medicine. We have an important opportunity to build on these strengths, accelerate innovation, and translate Canadian innovations into new therapies, high-quality jobs and economic growth. Congratulations to the Stem Cell Network on 25 years of advancing Canadian science and bringing together the people and partnerships, like we see at the Till & McCulloch Meetings, that are helping shape the future of health,” said the Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions. 

International scientific leaders take centre stage

The conference features an outstanding lineup of Canadian and international speakers, including two internationally recognized scientists whose pioneering research has helped transform the field of regenerative medicine.

Dr. Shinya Yamanaka of Kyoto University and the Gladstone Institutes will reflect on two decades of progress in induced pluripotent stem cell (iPSC) research, exploring advances in iPSC-based therapies and drug discovery, their potential clinical applications, and the opportunities and challenges ahead.

Closing the conference, Dr. Sergiu Pasca of Stanford University will highlight how stem cell-derived models of the human brain are deepening our understanding of brain development and neuropsychiatric disorders, while creating new opportunities for therapeutic development.

The conference will also celebrate outstanding Canadian research through its signature award lectures.

Dr. Stephanie Xie of the Princess Margaret Cancer Centre at University Health Network will deliver the prestigious Till & McCulloch Lecture, highlighting her award-winning research published in Nature. Her presentation, “When blood stem cells remember: how inflammation shapes aging and cancer risk,” will explore how exposure to inflammation can leave lasting changes in blood stem cells, with important implications for understanding aging and cancer.

Dr. Songtao Dong of the University of Toronto will deliver the Drew Lyall Award of Excellence Talk, presenting his top-ranked research abstract on an innovative approach to editing muscle stem cells to address Duchenne muscular dystrophy.

Building connections and supporting the next generation

Beyond the scientific presentations, TMM2026 will provide opportunities for researchers, trainees, and industry leaders to exchange ideas, build professional networks, and explore emerging opportunities across the regenerative medicine field.

The program includes five plenary sessions, the popular Meet the Experts Luncheon, and special sessions examining timely issues such as workforce development in an AI-ready bioeconomy and the importance of incorporating patient priorities into research and therapeutic development.

Supporting the next generation of scientific leaders remains a central focus of TMM. More than 200 poster and oral presentations will give trainees an opportunity to share their research, receive feedback from experts, and connect with potential mentors and collaborators.

As SCN celebrates its silver anniversary, TMM2026 offers an opportunity to recognize the achievements of Canada’s regenerative medicine community and the collective efforts driving the field forward.

For more information about the 2026 Till & McCulloch Meetings, including the conference program, visit www.tillandmcculloch.ca.

-30-

About the Till & McCulloch Meetings

The Till & McCulloch Meetings (TMM) is Canada’s premier stem cell, gene therapies, and regenerative medicine conference. Hosted annually by the Stem Cell Network, TMM brings together leading researchers, trainees, clinicians, industry experts, and other stakeholders from Canada and around the world to share scientific advances, foster collaboration, and strengthen the regenerative medicine community.

About the Stem Cell Network

The Stem Cell Network (SCN) is a Canadian not-for-profit that supports stem cell and regenerative medicine research; training the next generation of highly qualified personnel; enabling knowledge mobilization of research; and enhancing the commercialization readiness of stem cell and RM innovations. From the lab to the clinic, SCN’s goal is to power life-saving therapies and technologies through regenerative medicine research for the benefit of all. Created in 2001, with support from the Government of Canada, the Network has funded over 280 research projects and 30 clinical trials, cumulatively driven by experts from 350 research groups across Canada. Since its inception, over 28 biotech companies have been catalyzed or enhanced and more than 7,900 highly qualified personnel have been trained. In 2023, the Government of Canada announced additional funding for SCN through the Strategic Science Fund that will support SCN activities and research through to the end of the decade. Learn more: https://stemcellnetwork.ca/